Navigation Links
Immune Targeting Systems and WCCT Global Announce a New Influenza A H1N1 Virus to Support the Experimental Human Viral Challenge Model
Date:8/18/2014

CYPRESS, Calif. and LONDON, Aug. 18, 2014 /PRNewswire-iReach/ -- Immune Targeting Systems (ITS), specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A. To determine the effectiveness of FlunisynTM ITS produced its own live influenza challenge agent derived from the recently circulating Influenza A/California/2009 (H1N1) virus. This challenge virus, manufactured in compliance with the high level of quality and characterization required by the U.S. FDA and other Regulatory Agencies, has a much better infectivity profile than reported for similar challenge viruses.   Whilst the main purpose in developing its own challenge virus was to advance the development of FlunisynTM and to further understand the natural course of influenza illness, ITS wants to make the virus available to enable and support the development of new antiviral drugs and vaccines.

Photo - http://http://photos.prnewswire.com/prnh/20140815/136447

Immune Targeting Systems announced today an asset purchase agreement with WCCT Global (WCCTG) for ITS' proprietary developed challenge strain. Through this partnership, WCCTG has become the only commercial company offering sponsors the ability to do large scale influenza challenge studies in the United States.  The Experimental Human Viral Challenge Model has become widely accepted as an alternative to traditional early stage field trials to show the efficacy of antiviral and vaccine therapies.    The WCCTG facility in Costa Mesa, California, has been completely reconfigured to provide private rooms, separate ventilation and other standard containment provisions to accommodate this valuable research model and ensure the safety and comfort of the volunteers and staff. 

Benjamin Chen, PhD, CEO of Immune Targeting Systems said, "We are very excited that WCCT Global has taken over the ownership of this important clinical research tool and are confident that they will use the virus to help support the development of new vaccines and antiviral drugs".  Kenneth Kim, MD, CEO of WCCT Global said, " The capability to carry out the experimental influenza challenge model in conjunction with our deep-seated expertise in anti-viral drug development will surely be of great interest to our sponsors. This new capability combined with our Full Service Global capabilities, specialized influenza project teams, and deep scientific knowledge allows WCCTG to manage vaccine and antiviral development programs from First in Man through NDA submission."

More about Immune Targeting Systems

Immune targeting Systems, Ltd develops T-cell vaccines to highly mutated viruses and to cancers. The company's lead product  Flunisyn™ vaccine has been shown in three clinical studies to stimulate the production of T-cells that recognise and destroy influenza-infected cells. Flunisyn™  is a pan-influenza A vaccine applicable to multiple influenza strains without the need to be re-manufactured for each influenza season or pandemic outbreak.  The Company is also advancing the development of two other product candidates: a therapeutic Hepatitis B vaccine for chronic hepatitis B and a cancer vaccine for solid tumours. ITS is supported by Novartis Venture fund, Truffle Capital, HealthCap, Esperante Ventures and SME wholesale Finance.

More about WCCT Global

WCCT Global is a multi-site, full service pharmaceutical contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries.. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management, patient recruitment services, and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, influenza, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Renal, and Vaccines. 

Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE WCCT Global
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
2. Novimmune Reports Successful Completion of Phase I trial for NI-0101
3. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
4. UMD Researcher Helps Arm the Immune System to Fight Cancer
5. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
6. BHI Elects MedImmunes Reg Seeto, M.D. to Board of Directors
7. Global Autoimmune Disease Diagnostics Market
8. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
9. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
10. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
11. Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
Breaking Medicine News(10 mins):